<DOC>
	<DOCNO>NCT02681094</DOCNO>
	<brief_summary>The aim study evaluate safety efficacy therapy saxagliptin 5mg co-administered dapagliflozin 5mg , compare therapy saxagliptin 5mg dapagliflozin 5mg patient inadequately control ≥1500mg/day metformin monotherapy .</brief_summary>
	<brief_title>A Multi-Center , Randomized , Double-Blind , Phase III Trial Evaluate Safety Efficacy Saxagliptin Co-administered With Dapagliflozin Compared Saxagliptin Dapagliflozin All Given add-on Therapy Metformin Subject With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Patients age ≥18 year old time informed consent ; 2 . Patients Type 2 diabetes mellitus ( T2DM ) define HbA1C≥7.5 % ≤10.0 % screen visit ; 3 . Stable metformin therapy least 8 week prior enrolment dose ≥1500mg per day ; 4 . BMI ≤45.0kg/m2 Enrolment visit ; 5 . Fasting Plasma Glucose ( FPG ) ≤ 270mg/dl ( 15.0mmol/L ) enrolment visit ; 6 . For Females Only : Women childbearing potential ( WOCBP ) must use acceptable method contraception avoid pregnancy throughout study least 4 week last dose study medication manner risk pregnancy minimize . 1 . History diabetes insipidus , Type 1 diabetes Latent Autoimmune Diabetes Adults , diabetic ketoacidosis hyperosmolar nonketotic coma Symptoms poorly control diabetes would preclude participation trial include limited mark polyuria polydipsia great 10 % weight loss 3 month prior Enrolment ( Visit 1 ) , sign symptom . 2 . History pancreatitis . 3 . Administration antihyperglycaemic therapy , metformin , 14 day ( consecutive ) 8 week prior enrolment 4 . Any use DPP4 inhibitor SGLT2 inhibitor within 8 week prior enrolment . 5 . Significant hepatic disease , include , limited , chronic active hepatitis and/or severe hepatic insufficiency and/or significant abnormal liver function , include patient Alanine transaminase ( ALT ) and/or Aspartate transaminase ( AST ) ≥3x ULN ( Upper Limit Normal ) and/or Total Bilirubin ≥2.0x ULN . History severe hepatobiliary disease hepatotoxicity medication . Positive serologic evidence current infectious liver disease , include patient know positive Hepatitis viral antibody ImmunoglobulinM ( IgM ) , Hepatitis B surface antigen , Hepatitis C virus antibody . 6 . Moderate severe impairment renal function [ define Estimated Glomerular Filtration Rate ( eGFR ) &lt; 60milliLitre/min/1.73 m2 ( estimate Modification Diet Renal Disease ( MDRD ) ) serum creatinine ≥1.5mg/dL male ≥1.4mg/dL female ] . Conditions congenital renal glucosuria , history unstable rapidly progress renal disease . 7 . History clinically significant disease disorder , opinion investigator , may put patient risk participation study , may influence result , may limit patient 's ability participate complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Diabetes Mellitus Type 2 ,</keyword>
	<keyword>saxagliptin ,</keyword>
	<keyword>dapagliflozin ,</keyword>
	<keyword>metformin</keyword>
</DOC>